GLP-2-TZ

GLP-2-TZ (Tirzepatide) is a synthetic dual GLP-1 and GIP receptor agonist peptide engineered for simultaneous activation of both incretin pathways. It is studied in research for its dual-agonist receptor pharmacology, incretin signaling dynamics, and metabolic pathway modulation in preclinical models.

Tirzepatide is a synthetic dual GLP-1/GIP receptor agonist peptide engineered for balanced engagement of both incretin receptor pathways. It is studied in research for dual-agonist pharmacology and incretin signaling dynamics. Supplied as a lyophilized research peptide.

Tirzepatide was developed through systematic peptide engineering to create a single molecule capable of engaging both GLP-1R and GIPR with balanced potency. Its design incorporated a C-20 fatty diacid moiety for albumin binding and extended pharmacokinetics. Published research has characterized its unique dual-receptor pharmacology and signaling profile.

Published preclinical and clinical research has characterized Tirzepatide's balanced dual agonism at GLP-1R and GIPR, distinguishing it from selective GLP-1R agonists. Studies have examined its effects on glucose-dependent insulin secretion, glucagon dynamics, and metabolic signaling parameters. Its unique biased agonism profile at GLP-1R and its GIPR engagement have been subjects of detailed pharmacological characterization.